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Abstract
Background The appropriate role for surgery and endo-
vascular therapy for severe intermittent claudication (IC)
remains controversial. We present our results after
infrainguinal autogenous bypass for severe IC more than
10 years ago giving a reasoned argument to perform vein
bypass as the primary procedure for severe IC.
Methods Our prospectively designed database includes
more than 1,000 infrainguinal bypasses following an all-
autogenous policy. For this review only patients operated
on for severe IC at least 10 years ago were included. The
primary end points were survival and primary and assisted-
primary patency rates.
Results From October 1988 until December 2000, 124
bypasses for IC were performed. Ninety-five patients were
male and the mean age was 64.5 ± 10.8 years. Survival
after 10 years was 50.3% according to life table analysis.
Forty bypasses were to the supragenicular artery, 62 to the
infragenicular popliteal artery, and 22 to the tibial artery.
Thirty-day mortality was 0.8% (1 patient). The primary
patency rate after 10 years was 63.5% and the assisted-
primary patency rate 87.3%.
Conclusion Infrainguinal venous bypass for severe IC has
excellent long-term results. Our results are strong argu-
ments against the liberal use of stenting long lesions of the
femoropopliteal artery. Venous bypass remains the primary
procedure for TASC C and D lesions in claudicants.
Introduction
The appropriate role for surgery and endovascular therapy for
severe intermittent claudication (IC) remains controversial.
In recent years endovascular procedures became increasingly
important as therapy for limiting claudication. In 2000, the
Trans-Atlantic Inter-Societal Consensus (TASC) introduced
a classification scheme for superficial femoral artery (SFA)
occlusive disease and proposed guidelines for its manage-
ment [1]. In 2007, the updated treatment guidelines of the
TASC II report were published, which further refined the
treatment guidelines based on morphological stratification for
aortoiliac and femoropopliteal occlusive disease [2]. For
patients with IC and TASC A and B lesions, percutaneous
transluminal angioplasty and selective stenting (PTA/S) is
the preferred initial therapy. For patients with low operative
risk and TASC C and D lesions, greater saphenous vein
bypass (GSVB) should be considered [3–5]. Nevertheless,
there is an ongoing debate on whether PTA/S or bypass is
indicated for superficial femoral artery TASC II C and D
disease [6]. With that in mind, the role of GSVB is margin-
alized, especially for patients with IC. We present our results
of infrainguinal autogenous bypass for IC that was performed
more than 10 years ago and give a well-supported argument
for performing GSVB as the primary procedure for severe IC.
Methods
Since 1988 all infrainguinal autogenous bypasses performed
at our institution are recorded prospectively in a database. For
this study we reviewed more than 1,000 bypasses that fol-
lowed an all-autogenous policy. Harvesting and quality con-
trol of the vein are performed as described in a prior
publication [7].
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For this review, patients operated on for severe IC
(walking distance\200 m) at least 10 years ago and failed
nonoperative management, e.g., walking training, were
included. All patients were preoperatively evaluated for
cardiac disease according to ACC/AHA guidelines [8]. If
considerable cardiac disease was found, the operation was
postponed until successful coronary artery revasculariza-
tion (coronary artery bypass grafting [CABG] or coronary
artery stenting) was performed. If this was not possible, the
operation was cancelled and the patient was referred to the
best medical treatment possible.
Follow-up was every 3 months during first year and than
annually. If a patient missed follow-up, he was invited
again and a phone call to his physician was made. There-
fore, there was a low dropout rate during follow-up. All
patients received oral anticoagulation with Coumadin
(Bristol-Myers Squibb) postoperatively. Six months after
the procedure, the treatment was changed to aspirin alone
in patients with supragenicular bypasses and control duplex
without signs of stenosis.
The primary end points were survival and primary and
assisted-primary patency rates. Secondary patency is not
appropriate since occluded bypasses were not reopened but
redone. Results were reported according to the recom-
mended SVS reporting standards [9].
Results
From October 1988 through December 2000, 124 infrain-
guinal venous bypasses were performed for IC in 110
patients. Patient demographics are listed in Table 1. Mean
age was 63.7 ± 12.1 years. Ninety-five patients were male
(77%). Surgery was performed for severely limiting clau-
dication (Fontaine stadium IIB) in all patients. The site of the
distal anastomosis in 40 (32%) cases was to the suprageni-
cular popliteal artery, in 62 (50%) the infragenicular artery,
and in 22 (18%) the tibial artery. In 107 patients (86%), one
piece of greater saphenous vein could be used, and in 17
patients (14%), spliced veins, including arm veins, were
necessary following our all-autogenous policy. Fifteen
patients (12%) needed CABG during follow-up.
Mean follow-up time was 76.6 ± 58.3 months (Table 2).
One patient died on postoperative day 5 due to myocardial
infarction yielding an in-hospital and 30-day mortality of
0.8%. After 10 years of follow-up, the life-table survival rate
was 50.3% (SE ± 5.42%). Primary patency rate after
10 years was 63.5% (SE ± 7.50%) and assisted-primary
patency rate was 87.3% (SE ± 5.19%). Both patency and
survival rate showed a continuous decline without a sharp
drop, as seen in Figs. 1 and 2. Patency rates of spliced and
nonspliced vein bypasses were not different.
Discussion
With the recent explosion in technological advances,
accepted consensus no longer seems valid. TASC II C
lesions and, increasingly, TASC II D lesions are treated
with primary endovascular therapy [10–12]. Primary
patencies after these interventions range from 54 to 63%
after 1 year [10–12] and 22% after 4 years [10]. Today
so-called full-metal-jacket stenting of the superficial fem-
oral artery is being done with promising results [13]. Shah
et al. [13] reported a median primary patency of 55% after
6 months. They report a limb salvage rate of 85% while
65% of the patients were claudicants. This study shows
how patients with IC present with critical ischemia fol-
lowing failure of their endovascular operation.
The RESILIENT randomized trial, a multicenter random-
ized study, compared primary stenting to balloon angioplasty,
with provisional stent implantation for moderate-length
Table 1 Patient demographics and characteristics (n = 124)
n %
Gender (female/male) 29/95 23/77
Side (left/right) 64/60 52/48
Age (years) 64.5 (±10.8, range = 38–86)
Diabetes 30 24
Tobacco use 52 42
Hypertension 34 27
Site of distal anastomosis
Supragenicular 40 32
Infragenicular 62 50
Tibial 22 18
Vein conduit
One piece of GSV 107 86
Spliced and arm veins 17 14
Bypass on both legs 14 11
CABG during follow-up 15 12
GSV Greater saphenous vein, CABG coronary artery bypass grafting
Table 2 Results of infrainguinal venous bypass (n = 124)
Follow-up mean (months) 76.6 ± 58.3
Mortality (30 days) 1 (0.8%)
Survival rate after
10 years (life-table)
50.3% SE 5.42%
Occlusion rate (total) 13 (9%)
Primary patency after
10 years (life-table)
63.5% SE 7.50%
Primary assisted patency after
10 years (life-table)
87.3% SE 5.19%
SE standard error
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lesions and for patients with intermittent claudication [14].
Primary patency at 12 months was 81.3% for the stent group
versus 36.7% for the PTA group. The authors concluded that
longer lesions of the superficial femoral artery are better
treated with PTA/S than with PTA alone.
Ferreira et al. [15] report a primary patency rate of 69%
after 4.8 years and an assisted-patency rate of 90% after
5 years in stented SFAs. The length of the lesions ranged
from 3 to 53 cm (mean = 19 cm). Most of the patients
(61%) had TASC D lesions. Most of the patients (97.8%)
had limiting claudication. These good results are dampened
by the fact that three patients had to undergo amputation
following failed reopening of occluded stents.
Endovascular treatment of the infrapopliteal arteries is
discussed by Krankenberg et al. [16]. They present 78
patients with intermittent claudication and lesions of
the infrapopliteal arteries. After 12 months the primary
patency rate was 66.3%.
The difficult anatomic situations at the distal superficial
femoral artery and the popliteal artery are responsible for the
limitations of PTA and stenting. Laird [17] demonstrates the
difficulties specific to the femoropopliteal segment due
to repetitive deformation in multiple directions by leg
movement. This leads to stent fracture, which can be asso-
ciated with a higher risk of restenosis. Scheinert et al. [18]
investigated the incidence of femoral nitinol stent fractures
by radiographic screening in 93 patients at a mean follow-up
of 10.7 months after stent implantation. They found stent
fractures in 45 (37.2%) of 121 treated legs. The primary
patency rate at 12 months was significantly lower for
patients with stent fractures (41.1% vs. 84.3%, P \ 0.0001).
In-stent stenosis and stent occlusion are not benign. In
the study by Sabeti et al. [11], one third of the patients had
deterioration of their tibial arterial runoff. Recent results of
clinical outcomes and implications of failed infrainguinal
endovascular stents are presented by Gur et al. [19]. They
found that TASC C and D lesions are more likely to fail
with occlusion, lose runoff vessels, and alter the site of
subsequent open operation than their TASC A and B
counterparts. They stated that although these complications
are infrequent, they may negatively impact later attempts at
revascularization [19].
Both the superficial femoral artery and the suprageni-
cular popliteal artery are commonly involved in TASC C
and D lesions. In our patients we had to perform 22 (18%)
bypasses to tibial arteries. Our long-time results are
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supported by several published studies [20–22]. Therefore,
we believe that tibial bypasses can be justified in selected
well-informed patients with severe IC after conservative
treatment failed.
Our study has several limitations. Although prospec-
tively acquired, data have been retrospectively analyzed.
Due to the nature of cardiovascular disease, every long-
time follow-up study has to deal with a considerable loss of
patients, as shown at Fig. 2. After 10 years half of the
patients had died, mostly from cardiac problems. Further-
more, it is not possible to compare bypasses and endo-
vascular procedures since endovascular treatment was not
available at the time the bypasses were performed. Only a
prospective randomized study could compare the two
procedures. Due to the nature of the interventions, ran-
domization of patients would be very difficult to do. Fur-
thermore, the benefits of bypass are greater as time passes.
Therefore, conclusive results would be available only after
long-time follow-up.
In conclusion, the use of stenting in TASC C and D
disease may become a valuable alternative to bypass sur-
gery with future improvement of the endovascular arma-
mentarium. Until now, the published results do not justify
treating long femoropopliteal lesions by endovascular
means instead of surgical bypass.
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